Open AccessEffects of Antiproteinuric Intervention on Elevated Connective Tissue Growth Factor (CTGF/CCN-2) Plasma and Urine Levels in Nondiabetic Nephropathy
Author(s) -
Maartje C. J. Slagman,
Tri Q. Nguyen,
Femke Waanders,
Liffert Vogt,
Marc H Hemmelder,
Gozewijn D. Laverman,
Roel Goldschmeding,
Gerarda Navis
Publication year - 2011
Publication title -
clinical journal of the american society of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.755
H-Index - 151
eISSN - 1555-905X
pISSN - 1555-9041
DOI - 10.2215/cjn.08190910
Subject(s) - ctgf , medicine , endocrinology , losartan , kidney disease , proteinuria , nephropathy , fibrosis , kidney , urology , angiotensin ii , growth factor , blood pressure , diabetes mellitus , receptor
Connective tissue growth factor (CTGF/CCN-2) is a key player in fibrosis. Plasma CTGF levels predict end-stage renal disease and mortality in diabetic chronic kidney disease (CKD), supporting roles in intra- and extrarenal fibrosis. Few data are available on CTGF in nondiabetic CKD. We investigated CTGF levels and effects of antiproteinuric interventions in nondiabetic proteinuric CKD.